Osteopenia is a classification of bone mineral density that is below the young-adult reference range but above the densitometric threshold for osteoporosis. It indicates reduced mineral content in bone and is associated with increased fracture risk, although the risk varies substantially between individuals. Osteopenia is generally asymptomatic, does not inevitably progress to osteoporosis, and does not by itself establish a need for medication.
Definition and measurement
Bone mineral density is usually measured by dual-energy X-ray absorptiometry (DXA), most commonly at the hip and lumbar spine. DXA reports an areal density rather than a direct measurement of bone strength or three-dimensional density.
For postmenopausal women and men aged 50 years or older, results are commonly classified using a T-score, which expresses the number of standard deviations by which a measured bone density differs from the mean of a young-adult reference population:
The conventional categories are:
| Classification | T-score |
|---|---|
| Normal bone density | |
| Low bone mass, or osteopenia | |
| Osteoporosis |
These thresholds describe a continuum rather than a sharp biological boundary. “Low bone mass” or “low bone density” is often preferred to “osteopenia” because the latter can imply a distinct disease where the finding is primarily a measurement category.
In premenopausal women, men younger than 50, and children, Z-scores are generally preferred. These compare bone density with an age-appropriate reference population. A Z-score of or lower is described as “below the expected range for age”; the adult T-score categories are not routinely applied to these groups.
Biological basis and associated factors
Bone is continually renewed through bone remodeling, in which bone-resorbing cells remove existing tissue and bone-forming cells replace it. Low bone density can reflect a relatively low peak bone mass attained during growth, subsequent bone loss, or both.
Age-related changes and the decline in estrogen associated with menopause are important contributors. Genetic influences, body size, physical loading, and nutritional status also affect bone mass.
Other associated factors include:
- Prolonged immobility or reduced weight-bearing activity.
- Low body weight and malnutrition.
- Tobacco use and high alcohol consumption.
- Long-term exposure to glucocorticoid corticosteroids.
- Disorders affecting nutrient absorption, including celiac disease.
- Endocrine disorders such as hyperthyroidism and reduced sex-hormone production.
Some conditions, including chronic kidney disease, can alter bone turnover and mineral metabolism in ways that a DXA measurement alone cannot characterize.
Clinical significance and fracture risk
Osteopenia usually causes no symptoms. Its clinical importance lies chiefly in its association with fragility fractures—fractures resulting from low-energy trauma, such as a fall from standing height or less.
Bone density is only one determinant of fracture risk. Age, previous fractures, falls, family history, medication exposure, and aspects of bone structure also matter. Consequently, two people with the same T-score can have markedly different absolute risks.
Although an individual with osteoporosis generally has greater fracture risk than an otherwise similar individual with osteopenia, many fractures occur among people in the osteopenic range because this group is large. A low-trauma hip or vertebral fracture can establish clinical osteoporosis in relevant adult populations even when the T-score is above .
Risk-assessment tools such as FRAX combine clinical factors, with or without femoral-neck bone density, to estimate the 10-year probability of hip fracture and major osteoporotic fracture. Their estimates depend on the population model and do not incorporate every relevant risk factor.
Evaluation and interpretation
Assessment of low bone density considers the measurement alongside fracture history, medication exposure, associated illnesses, and other clinical findings. Laboratory investigations may help identify secondary causes when indicated.
Osteopenia is not synonymous with osteomalacia, a disorder of bone mineralization. Both can produce low bone-density measurements, but they have different underlying mechanisms. Similarly, a report of osteopenia on conventional radiography is a qualitative observation rather than a DXA-based T-score classification.
DXA has important limitations:
- Small body or bone size can lower areal density measurements without a proportionate reduction in volumetric density.
- Degenerative changes and other artifacts can falsely elevate measured spinal density.
- Positioning, equipment, and analysis differences can affect results.
- Small changes between scans may reflect measurement variability rather than true bone loss.
Serial measurements are therefore interpreted against the testing facility’s precision and least significant change.
Management context
Management is based on overall fracture risk and underlying causes rather than the osteopenia label alone. Clinical approaches can include addressing nutritional deficiencies, reduced mobility, fall risk, or secondary contributors to bone loss.
Bone-active medication is used in selected people with osteopenia when fracture history or estimated fracture probability indicates sufficiently high risk. Treatment thresholds differ among guidelines and healthcare settings. Not everyone with osteopenia receives medication, and the interval between bone-density measurements varies with baseline density and clinical circumstances.